ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.72
0.56%
US Tech 100
17,722.00
0.46%
S&P 500
5,214.08
0.51%
US Dollar vs CAD
1.36827
0.03%
Bitcoin
62,957.23
-0.15%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateTimeSourceHeadlineSymbolCompany
05/09/20247:00AMPR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
05/09/20245:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
05/09/20245:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/08/20247:00AMPR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
05/08/20245:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/01/20247:00AMPR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
04/11/20246:00AMPR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
03/28/20247:00AMPR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
03/25/20247:00AMPR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
03/07/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20247:00AMPR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
03/07/20245:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20245:07AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
03/06/20247:00AMPR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
03/06/20245:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/12/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/06/20247:00AMPR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/20247:00AMPR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
01/18/20247:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/18/20247:00AMPR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
12/19/20239:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
12/19/20237:00AMPR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
11/22/20233:15PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
11/13/20231:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
11/13/20231:45PMPR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
11/08/202312:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
11/08/20238:50AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
11/08/20237:00AMPR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
11/01/20238:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
11/01/20237:00AMPR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Your Recent History

USOTC
EMGE
Emergent Health (PK)
USOTC
TXTM
ProText Mobility (PK)
USOTC
SONG
Music Licensing (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
RDAR
Raadr (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
YCRM
Yuenglings Ice Cream (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
CLNV
Clean Vision (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
USOTC
ERHE
ERHC Energy (CE)
NASDAQ
NVDA
NVIDIA
USOTC
IQST
iQSTEL (QX)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved